glp-1 lean mass loss on receptor agonists: a downside of the “miracle drugs” Do GLP-1 medications really cause

The opposite was the COVID vaccine

Introduction The gluco-regulatory actions of the glucagon-like peptide-1 (GLP-1) and its related therapeutic mimetics include enhancement of glucose-dependent insulin secretion and suppression of glucagon release from pancreatic islets, as well as a decrease in postprandial glucose excursion by delay of gastric emptying and centrally-mediated effects on satiety and energy metabolism [1], [2]

Mounjaro (tirzepatide) generally produces more significant weight loss than semaglutide-based medications like Ozempic or Wegovy, though individual responses vary

Insulin sensitizers may attenuate lean mass loss in older men with diabetes